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968M ost medical treatments aredesigned for the average pa-tient, with a one-size-fits-
all-approach. Though successful for
many, this approach may not benefit
all patients. An improved understand-
ing of the function of genes, proteins,
metabolites, and personal and environ-
mental factors has led to a call for
personalized medicine: a tailored
approach to disease prevention and
treatment that considers inter-
individual differences in patients.
Despite some successes, especially
in oncology, personalized medicine isVOL. 109 NO. 6 / JUNE 2018
Fertility and Sterility®still in its infancy in reproductive medicine, possibly
because treatment success (live birth) is determined by
many baseline factors (in both males and females) and treat-
ment factors (surgical, endocrinological, gamete, embryo,
and uterine) (1). This review describes each of the main seg-
ments of the assisted reproductive technology (ART) patient
journey, starting from ovarian stimulation and ending in
live birth, addressing which aspects of patient care could
be personalized, both with respect to clinical care and to
future research.WHAT ARE THE AIMS OF FERTILITY
TREATMENT?
The main aim of fertility treatment is to enable infertile cou-
ples to have a baby, and live birth is therefore the preferred
primary outcome of clinical trials evaluating the effectiveness
of fertility treatments (2). In reality, intermediate pregnancy
outcomes (including chemical pregnancy rate, clinical preg-
nancy rate [CPR], and ongoing pregnancy rate [OPR]) are
most commonly evaluated, with only a minority of random-
ized controlled trials (RCTs) in reproductive medicine report-
ing live birth outcomes (3). However, as these intermediate
endpoints are, overall, strongly positively correlated with
live birth rates (LBRs) (4, 5), a comparison between
treatment groups may not be compromised. The positive
association between number of oocytes, number of good
quality embryos (GQE) and (cumulative) LBRs (6–8) suggests
that the number of oocytes retrieved and number of
embryos available may be relevant intermediate outcomes
for the comparison of various ART treatments. However, it
is uncertain if these outcomes are solely a consequence of
the treatment, or whether they are significantly influenced
by the intrinsic characteristics of the woman.
The safe delivery of a healthy baby may take several
treatment cycles; therefore, the cumulative LBR per patient
starting treatment is a key outcome variable. These cumula-
tive LBRs are influenced by treatment efficacy (LBR per
started treatment cycle) and intra- and inter-cycle discontin-
uation of treatment. While there is a lot of focus on efficacy,
patient care is equally as important, as shown by the high
discontinuation rates observed during ART treatment in
both countries with low reimbursement rates (45% in the
U.S. [9]) and countries with public reimbursement (48%–
65% in the Netherlands [10], Canada [11], and Sweden
[12]). Trials have shown that in systems without funding lim-
itations, psychological stress is the most common reason for
drop-out from ART treatment (13–16). A personalized
management strategy, taking into account quality of care
(17), targeting patient expectations, and aimed at
minimizing the treatment burden and side effects as much
as possible, with informed and shared decision-making be-
tween patients and healthcare professionals, could alleviate
the psychological stress. Such a strategy could lead to reduced
discontinuation rates and impact favorably on ART treatment
outcomes by shortening the time interval between the start of
treatment and conception leading to live birth. Pregnancy
loss should always be incorporated in clinical decision mak-
ing, owing to its psychological impact (4).VOL. 109 NO. 6 / JUNE 2018Another important consideration is safety, and particu-
larly the potential for complications arising either directly
from fertility treatment or through pregnancy or delivery.
For example, while two healthy babies born from a twin preg-
nancy at term may be considered a good outcome for some
patients (18), multiple pregnancy increases the risk of compli-
cations for both mother and babies. Achieving a singleton
pregnancy should therefore be considered an important aim
of treatment. Additional considerations that are relevant for
patients and professionals are the time taken to achieve a
live birth (19), cost and quality of care, and quality of life (20).
Time to pregnancy is of particular importance because
infertility and its treatment are distressing, with couples
wanting pregnancy to occur as soon as possible (19). When
endpoints such as time to pregnancy are evaluated, a standard
time frame should be used (e.g., time after randomization) to
ensure comparability. This has not yet been adequately
defined, with the latest International Committee Monitoring
Assisted Reproductive Technologies (ICMART) glossary
defining time to pregnancy as, ‘‘The time taken to establish
a pregnancy, measured in months or in numbers of menstrual
cycles’’ (21). We propose that time from treatment initiation
(defined as the start of hormonal treatment for ovarian stim-
ulation) to a clinical pregnancy (diagnosed by ultrasono-
graphical visualization of one or more gestational sacs or
definitive clinical signs of pregnancy [21]) that results in a
live birth should be reported rather than the time to live birth,
as this provides a standard starting point and will control for
the gestational period.
Financial costs are also an important outcome: in a pri-
vate healthcare system costs can determine whether a treat-
ment is affordable and in a public healthcare system they
can determine the overall accessibility of fertility treatment,
including the number of ART cycles that are reimbursed per
patient.
The individual expectations of patients should be well
understood before treatment is started, to better enable
personalization of the approach, and success based upon
these expectations should form the basis of any treatment
evaluation (22, 23).EVALUATING PRECISION MEDICINE DURING
THE ART TREATMENT JOURNEY
Controlled Ovarian Stimulation
The aim of controlled ovarian stimulation (COS) is to optimize
the number of oocytes retrieved, so that sufficient oocytes can
be safely obtained for ART treatment. Ovarian response is
associated with the success of ART treatment (8, 24, 25).
Pituitary suppression protocol. According to three meta-
analyses (26–28), gonadotropin-releasing hormone (GnRH)
antagonist treatment is associated with a similar LBR
compared with GnRH agonist treatment but with a lower inci-
dence of any grade of ovarian hyperstimulation syndrome
(OHSS). The reduced risk for OHSS is possibly also related to
the use of a GnRH agonist instead of human chorionic gonad-
otropin (hCG) to trigger final oocyte maturation (29). In one
meta-analysis (28)—the methodology of which has been969
VIEWS AND REVIEWScriticized (30)—a lower OPR was observed after antagonist
treatment in the overall population but not in women with
polycystic ovary syndrome (PCOS) or in women with poor
ovarian response (POR). Overall, the GnRH antagonist proto-
col can be proposed for patients with expected normal or high
ovarian response. However, there are not sufficient data to
warrant abstaining from using antagonist protocols in poor
responders.
Gonadotropin dose: starting dose and dose adjustment.
Ovarian reserve markers, including basal follicle-stimulating
hormone (FSH), basal estradiol, inhibin B, antral follicle count
(AFC), and anti-M€ullerian hormone (AMH), are often used as
predictors of ovarian response and for selection of the FSH
dose. AFC and AMH have the highest accuracy for predicting
poor and excessive response following ovarian stimulation
(OS) (31). Individual patient data meta-analyses have indi-
cated that poor response is predicted by AFC <7 and AMH
<1.1 ng/mL (32–34) and hyper response by AFC >14 (35,
36) and AMH >3.5 ng/mL (37, 38).
An individualized follitropin alfa starting dose based on
a nomogram (age, basal FSH, and AMH) resulted in a higher
proportion of women obtaining the stated target of 8–14 oo-
cytes compared with a fixed 150 IU dose (63% vs. 42%) (39).
However, this superiority could not be confirmed for a
similar reproductive outcome (proportion of women obtain-
ing 5–12 oocytes) in another trial comparing treatment with
either a fixed or an individualized gonadotropin starting
dose (25). This was possibly because a mixture of follitropin
alfa originator and biosimilar drugs were used in both treat-
ment arms (and biosimilars differ from originators with
respect to chemical structure, preclinical activity, and clin-
ical effect) and/or a different nomogram was used (age,
body mass index [BMI], AFC, and AMH). In non-
inferiority trials evaluating individualized versus fixed
starting-dose regimens for the primary outcomes of OPR
(40) or number of oocytes retrieved (41), any conclusions
suggesting non-inferiority (40) or lack of non-inferiority
(41) can be challenged; both treatment arms were different
with respect to starting dose, type of gonadotropin used
(40) and dose adjustment policy (only allowed in control
group) (40, 41).
However, no study, due to the small sample size, has
shown that individualizing FSH starting dose based on
ovarian response markers improves LBR (42). For predicted
normal responders, more oocytes were retrieved with 200–
225 IU FSH daily compared with 100–150 IU daily, with no
significant difference observed with 225 IU compared with
300 IU daily (42). In predicted low responders, daily gonado-
tropin doses R300 IU were associated with a greater number
of oocytes retrieved and significantly lower cycle cancellation
due to poor response compared with doses of 150 IU, but LBRs
were not improved by the higher dose (42). Similarly, the
OPTIMIST study in predicted poor responders (AFC <10)
showed that individualized FSH dosing (225 or 450 IU) was
associated with a greater number of oocytes retrieved, a
reduced incidence of cycle cancellation (4–8% vs. 30%), and
a similar LBR compared with a standardized dose of 150 IU
FSH (43).970In ameta-analysis (44) of three RCTs in poor responders, a
higher number of oocytes retrieved but similar CPRs were
observed in women after COS with a ‘‘higher’’ gonadotropin
starting dose (450 IU [two RCTs] or 600 IU [one RCT])
compared with COS using a ‘‘lower’’ gonadotropin starting
dose (300 IU [two RCTs] or 150 IU [one RCT]).
The data presented suggest recommended starting doses
of 150–225 IU and 225–300 IU for predicted normal re-
sponders and predicted poor responders, respectively.
In expected hyper responders, lower FSH doses should be
used, as they reduce the risk for OHSS without compromising
success rates. The OPTIMIST study (45) in predicted hyper re-
sponders (AFC >15) showed that a 150 IU daily dose of FSH,
compared with a 100 IU daily dose, significantly increased the
number of oocytes retrieved and was associated with a lower
first cycle cancellation rate (12% vs. 24%). However, the
higher daily dose was also associated with a higher risk of
mild-to-moderate OHSS (11% vs. 4%). More studies are
needed to identify the optimal gonadotropin starting dose
in expected high responders, taking into account not only
reproductive outcomes but also the risk for OHSS and cycle
cancellation.
Although dose adjustment has been allowed in most cur-
rent trials, no robust trials have evaluated the effect on LBR of
FSH dose adjustment during treatment (45). Individual dose
adjustment after a first failed cycle and dose adjustment dur-
ing OS are important areas of future research.
Minimal/mild ovarian stimulation. Minimal/mild OS regi-
mens are advocated as a cost-effective alternative to conven-
tional OS, but there is no standardized regimen for minimal
stimulation. Suggested strategies include the use of anti-
estrogens (e.g. clomiphene citrate) and/or aromatase inhibi-
tors (e.g. letrozole), either alone or in combination with
low-dose gonadotropins. While a recent meta-analysis
observed that mild OS protocols reduced the amount of
gonadotropin required and the incidence of OHSS, these pro-
tocols were also associated with a significant increase in the
incidence of cycle cancellations, as well as reductions in the
mean number of oocytes retrieved. Furthermore, no conclu-
sive evidence for live-birth or pregnancy rates in both the
general population and women with POR was seen (46).
More evidence is needed before minimal/mild regimens are
adopted into clinical practice (46); this should also take into
account time to pregnancy and treatment discontinuation
rate.
Oocyte triggering. In spontaneous ovulation cycles, FSH and
luteinizing hormone (LH) show a mid-cycle surge, whereas
triggering of final oocyte maturation in COS protocols tradi-
tionally relied solely on the activity of hCG to mimic the LH
surge. More recently, triggering with a GnRH agonist has
been employed in GnRH antagonist cycles to stimulate the
LH surge. Ameta-analysis of 17 trials observed that triggering
with a GnRH agonist instead of hCG in fresh autologous
in vitro fertilization (IVF)/intracytoplasmic sperm injection
(ICSI) cycles (13 trials) reduced the risk for OHSS but resulted
in a much lower LBR (29). However, a more recent meta-
analysis of five trials of a GnRH agonist trigger followed by
luteal phase support (LPS) with LH activity versus hCG triggerVOL. 109 NO. 6 / JUNE 2018
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significantly between the groups. Optimization of LPS is
needed to further limit OHSS in normal responder patients.
In addition, no difference in the risk of OHSS was reported
(OHSS occurred in 4/413 patients receiving GnRH agonist
and 7/413 patients receiving hCG) (47). In donor–recipient cy-
cles (four trials) there was no difference in LBR or OPR (29).
A meta-analysis of four trials observed a significantly
higher pregnancy rate with dual trigger (hCG and GnRH
agonist) compared with hCG alone (48). However, no signifi-
cant differences were observed between the groups in the
number of oocytes retrieved, number of mature oocytes
retrieved, number of fertilized oocytes, number of good-
quality embryos or implantation rate (IR) (48). Collectively,
these data suggest that a GnRH agonist trigger could be useful
for women undergoing freeze-all cycles, women donating oo-
cytes, and women freezing their oocytes for fertility preserva-
tion. However, despite the reduced risk for OHSS, a few cases
of severe early-onset OHSS have been reported, indicating
that further fine-tuning of individualized LPS might improve
results even further.
Fresh embryo transfer (ET) should not be disregarded and
a GnRH agonist trigger can be used to obtain a high LBR with
a low risk for OHSS. An analysis of the cost-effectiveness and
impact on the patient of GnRH agonist trigger and LPS
compared with hCG (the gold standard trigger) would better
enable the clinical significance of both options to be judged.ART Laboratory Procedures
Sperm diagnostic tests. Compared with oocyte yield optimi-
zation and embryo selection, considerably less research effort
has gone towards improving sperm yield and selection. Tests
have been proposed to assess aspects including motility pat-
terns (using computer-derived measures), chromatin errors,
and apoptotic markers. However, none of these tests has
been evaluated thoroughly and few are used routinely in
the clinic.
A high degree of sperm DNA fragmentation is associated
with poorer pregnancy rates and LBRs in couples trying to
conceive naturally, by intrauterine insemination (IUI) and un-
dergoing routine IVF, but not when ICSI was used (49–51).
Meta-analysis also showed that the assay used to analyze
DNA fragmentation can also have an impact on the correla-
tions: the terminal deoxynucleotidyl transferase (TdT) dUTP
nick-end labeling (TUNEL) assay and the single-cell gel elec-
trophoresis (COMET) assay have better predictive capacity
than the sperm chromatin structure assay (SCSA) and sperm
chromatin dispersion (SCD) test (52). A major disadvantage
of DNA fragmentation testing is that the assay renders the
tested sample unsuitable for clinical use. Studies are needed
to confirm prospectively the hypothesis (49–51) that, in
couples with a high degree of sperm DNA fragmentation,
ART treatment with ICSI leads to a higher OPR and LBR
than ART treatment with IVF.
When DNA damage is suspected, intra-cytoplasmic
morphologically selected sperm injection (IMSI) could be
used; for example, in cases of oligoasthenoteratozoospermia,
with or without recurrent implantation failure after ICSI. AVOL. 109 NO. 6 / JUNE 2018meta-analysis reported improved implantation and preg-
nancy rates after motile sperm organelle morphology exami-
nation (MSOME) for couples with previous ICSI only or male
factor infertility (53). These findings were reiterated in a sys-
tematic review of 22 trials (54), but studies reporting on LBR
after MSOME followed by ICSI (IMSI) compared with ICSI
alone are of poor quality (55). In summary, while the concept
of advanced sperm selection shows potential for personal-
izing the treatment approach, there are no studies that
demonstrate its clinical value.
Type of insemination/fertilization. The type of fertilization
method is another possibility for individualization, whereby
the selection criteria for IUI, IVF, or ICSI is often based on a
couple's reproductive and clinical history, sperm diagnostic
tests, and ‘‘post-preparation’’ sperm recovery and motility
rates (56). Variable concentrations of viable sperm have
been used as indicators for changing from IUI to IVF. One
study reported that IVF should be selected if fewer than 10
million viable sperm are present in the total ejaculate (57),
whereas other studies recommend this concentration in a pro-
cessed sample (58). For ICSI, there is no cut-off value except
sufficient viable sperm, and ICSI should be considered in cases
where the sperm sample is poor (59), there is low ‘‘post-prep-
aration’’ yield (often specified as a total number of sperm less
than 1million), previous fertilization failure (56) or in cases of
surgically retrieved sperm (60).
Regarding implantation, a large data analysis showed
that, compared with conventional IVF, ICSI was not associ-
ated with improved LBRs per transfer, irrespective of the pres-
ence of a diagnosis of male factor infertility (61). This finding
was also supported by an RCT in couples with non-male factor
infertility (62). However, a meta-analysis of studies where sib-
ling oocytes were split between IVF and ICSI suggested that
ICSI might increase fertilization rates and decrease risk of to-
tal failure to fertilize in couples with well-defined unex-
plained infertility (63), although this has not been evaluated
in a RCT.
Embryo culture, selection, and day of transfer. Since only a
limited number of fertilized oocytes/cleavage stage embryos
will become good quality blastocysts on day 5 (56, 64), the
number of retrieved oocytes, 2PN oocytes and/or the
number of good GQE on day 2/3 can be used to
individualize the selection of the day of transfer (65).
However, it is well known that a proportion of non-GQE at
day 2/3 will become good quality blastocysts (64).
Continuous embryo monitoring (CEM) systems enabled
by time-lapse technology (TLT) hold promise to improve
ART (66, 67). Such technology confers several practical
benefits to the IVF laboratory (68) and enables the
identification of abnormal embryo developments, including
direct or reverse cleavage, which have been shown to be
associated with reduced IR in retrospective studies (69, 70).
However, its potential to improve embryo selection and
therefore clinical outcomes is still under debate.
Recent studies have shown that fresh and frozen embryo
transfer (FET) result in similar LBR, opening the way to single
embryo transfer (SET) during both fresh and frozen cycles (71,
72). Assessment of embryo quality to identify the embryo971
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for SET, as appropriate embryo selection may reduce the time
to pregnancy and live birth by improving implantation rate
and reducing early pregnancy loss.
Pre-implantation genetic testing for aneuploidy. As over
half of the embryos produced by IVF are aneuploid, preim-
plantation genetic testing for aneuploidy (PGT-A) may iden-
tify embryos with optimal implantation potential, reduce the
number of ET, and time to pregnancy in ART (73–75). Clinical
outcomes are calculated as sustained implantation, referring
to the number of fetal sacs over 12 or 20 weeks of
gestation, and as pregnancy rates per transfer, per started
cycle or per patient (76).
Mosaicism originates from the first embryo cleavage
and can be identified by a trophectoderm biopsy analyzing
several cells. However, it is challenging to calculate the real
incidence of mosaicism in preimplantation embryos
because of technical limitations (77, 78). It is important
to note that the true incidence of mosaicism that could
impact the accuracy of the diagnosis should not be
higher than 6% (79) and the clinically recognizable error
rate after PGT-A is low (80). More recently, several studies
have proposed the possibility of transferring some types of
mosaic embryo as they might develop into healthy euploid
newborns, in particular when no euploid embryos resulted
from the aneuploidy testing and low levels of mosaicism
are detected in the biopsy (81–83).
In patients at advanced maternal age, overall, one or two
COS cycles are needed to obtain five MII oocytes that result in
at least one euploid blastocyst (76). Obviously, in low re-
sponders the number of cycles needed to obtain one euploid
embryo will increase but the only other option is to transfer
aneuploid embryos which are more likely to result in miscar-
riage or no pregnancy.
In both cleavage stage and trophectoderm biopsy,
extended embryo culture is needed, and ET is performed at
the blastocyst stage. This strategy could decrease the number
of embryos available for transfer in patients at advanced
maternal age, especially women <40 years old who are un-
dergoing PGT-A with a small cohort of available blastocysts
for biopsy. However, embryo IR with embryos not reaching
the blastocyst stage are poorer. In addition, it has been
recently suggested that morula can be biopsied on day 6,
but these morulae are associated with higher aneuploidy rates
and lower IRs compared with blastocysts (84).
A meta-analysis evaluated whether PGT-A with compre-
hensive chromosome screening (PGT-A-CCS) improves clin-
ical IR and sustained IR (beyond 20 weeks) compared with
routine care for embryo selection in IVF cycles. In three
RCTs (n¼659; all patients with normal ovarian reserve and
good prognosis) at the blastocyst level, PGT-A-CCS was asso-
ciated with a significantly higher clinical IR (73). However,
screening with PGT-A as well as extended culture increases
the risk of having no embryos for transfer, and comparative
trials should be based on LBRs per started cycle. In addition,
there are at present no conclusive strategies for reducing the
impact of varying levels of mosaicism. Therefore, although
PGT-A and selection of chromosomally euploid embryos972may reduce the miscarriage rate and shorten time to preg-
nancy, especially in women at advanced age (74, 75), it has
not been shown to improve cumulative LBR.
Embryo culture media. The addition of granulocyte-
macrophage colony-stimulating factor (GM-CSF), which is
reported to have a protective effect on embryo stress to the
embryo culture medium has been observed to have a modest
positive effect on ongoing IR (OIRs) at week 7 and also on
LBR, compared with control (85). Post-hoc analyses showed
that GM-CSF increased OIRs in women with more than one
miscarriage. However, this study had an adaptive design
and the positive effect of GM-CSF was not seen when human
serum albumin concentration in culture media was increased.
The addition of hyaluronic acid to the culture medium showed
moderate quality evidence of improvements in CPRs and LBRs
in a meta-analysis of 17 trials (86). Again, further RCTs are
required to assess whether these treatments are of benefit,
specifically in women with unexplained miscarriage.Personalizing Endometrial Receptivity
Embryo implantation depends not only on the embryo but
also on the endometrial window of implantation (WOI).
Supraphysiological levels of hormones during COS are asso-
ciated with modifications to the endometrium, including
greater endometrial advancement and altered gene expres-
sion (87–89). These modifications have been suggested to
have an impact on implantation and obstetric and
perinatal outcomes (90). The use of freeze-all strategies
has been suggested to optimize endometrial receptivity, as
the transfer will happen into a more ‘‘natural’’ endome-
trium. The protocols that can be used for FET are natural cy-
cle, modified natural cycle (ovulation is induced during a
natural cycle), artificial (hormone replacement treatment
[HRT]) cycle (endometrial receptivity is induced by exoge-
nous progesterone exposure after proper priming with
exogenous estradiol; GnRH agonist co-treatment may be
employed to down-regulate the pituitary and prevent follic-
ular growth) and stimulated cycles (gonadotropins are used
to induce follicular development and ovulation is triggered
with hCG).
A retrospective study of 1926 FET cycles performed using
either an artificial or stimulated protocol, observed that arti-
ficial cycles were associated with a greater incidence of early
pregnancy loss and a lower LBR compared with stimulated
cycles (91). A meta-analysis that included 20 studies did not
show differences in outcomes between the natural-cycle pro-
tocol, the modified natural cycle protocol or the artificial pro-
tocol (92). These data suggest that stimulated cycles might
provide improved outcomes compared with natural and arti-
ficial cycles, but this should be studied by direct comparisons
of the different protocols.
Another proposed method to improve endometrial recep-
tivity is mechanical endometrial injury, also called 'scratch-
ing'. This has been proposed to positively affect the chance
of implantation after ET, but the currently available evidence
(after 14 years of use) is not yet conclusive (93, 94). Ongoing
large clinical trials (e.g. The SCRaTCH study) (94–96) could beVOL. 109 NO. 6 / JUNE 2018
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might be related to beneficial treatment outcomes.
Identifying the window of implantation. Failure of implanta-
tion is considered a major cause of unexplained infertility,
with inadequate endometrial receptivity responsible for about
two-thirds of implantation failure (97). Although most
women (70%) will reach receptivity after 5 full days
(120 hours; Pþ5) of progesterone administration in HRT cy-
cles, or 7 days after the LH surge (168 hours; LHþ7) in natural
cycles, some others show a displaced (pre-receptive or post-
receptive) WOI, possibly leading to recurrent implantation
failure. Identification of a personalized WOI has been pro-
posed, to synchronize ET with the optimal receptive period
in a strategy known as personalized ET (pET). Endometrial
transcriptomics has been suggested as a reliable and objective
method for endometrial assessment according to its gene
expression pattern (98, 99), leading to the development of a
number of assays, including the endometrial receptivity
analysis (ERA) test (100), the E-tegrity test (101), the
endometrial function test (EFT) (102) and ReveptivaDx
(103).
These tissue profiling technologies use genomic and mo-
lecular markers to evaluate the endometrium and aim to assist
in optimizing treatment, including the implantation date, ac-
cording to each individual's characteristics. The ERA test
(https://www.igenomix.com/provider-tests/endometrial-rece
ptivity-test-era) is based on next generation screening (NGS)
of 236 genes identified as being involved in endometrial
receptivity and has shown clinical promise in patients who
repeatedly failed IVF (104, 105). The E-tegrity test is based
on immunohistochemical staining of single molecules such
as alpha-1, alpha-4, and beta-3 integrins (http://www.etegrity
test.com) (102), the EFT is based on detection of cyclin E and
cyclin-dependent kinase inhibitor p27 (http://klimanla
bs.yale.edu/infertility/eft/) (102) and endometrial BCL6 testing
is proposed for ReveptivaDx (103). Endometrial receptivity has
also been analyzed by immunohistochemical detection of uter-
ine natural killer (uNK) cells. However, the prognostic value of
measuring total uNK cells or CD56(þ) cells in endometrial
specimens remains uncertain (106).Embryo Transfer
The number of embryos transferred can be individualized ac-
cording to the viability of the embryos, the age of the woman,
and the number of previous (successful or unsuccessful)
transfers. In some parts of the world, SET policies, mandating
the transfer of a single embryo in the majority of cases, have
successfully reduced the incidence of multiple pregnancies.
However, in most countries, multiple pregnancies and births
continue to be a burden, and concentrated efforts are needed
to reduce this risk. Stricter SET policies for particular women,
including younger women, and encouraging women with a
high number of GQE towards SET and cryopreservation of
the excess embryos, rather than toward multiple ET, would
reduce multiple pregnancies. Good quality blastocysts ob-
tained during the first or second cycles in women aged
<36 years should be considered for SET, whereas women
with a POR phenotype receiving double-embryo cleavageVOL. 109 NO. 6 / JUNE 2018stage transfer during the first cycle have only a modestly
increased risk of multiple births (107).
Freeze all strategies. Data from two RCTs suggest that
freeze-all strategies do not benefit ovulatory women (71,
72). However, these trials did not analyze whether the
effectiveness of fresh or frozen transfer success varied
according to baseline characteristics that are biologically
linked to implantation, for example, increased progesterone
concentrations at the time of hCG triggering (108) or a thin
endometrium (109, 110). Indeed, observational data
support a negative impact on endometrial receptivity and
reproductive outcome from elevated progesterone
concentrations or endometrial thickness <7 mm determined
by vaginal ultrasound at the end of COS (109–113). These
biomarkers should be incorporated into the design of RCTs,
to evaluate if they can guide better treatment decisions.
Freeze-all strategies followed by FET could also be bene-
ficial for ovulatory women with increased risk for OHSS, but,
the cost-effectiveness of these strategies still requires evalua-
tion. Women with PCOS may benefit from a freeze–all strat-
egy with subsequent FET, as a higher frequency of live births
and a lower frequency of pregnancy losses has been observed
after FET rather than fresh transfer (114).
Early pregnancy Management
According to most current guidelines, early pregnancy man-
agement for both natural and ART conceived pregnancies is
similar, with the exception of LPS for ART pregnancies, as
indicated.
Luteal phase support. LPS aims to compensate for the
dysfunctional corpus luteum resulting from supra-
physiological estradiol levels during OS suppressing LH
levels.
Traditionally, patients who receive hCG to trigger oocyte
maturation receive LPS (either vaginal, oral, intra-muscular,
subcutaneous, or a combination) with progesterone (115). If
a GnRH agonist is used as a trigger, LPS may be challenging,
as there will be luteal phase insufficiency, although individual
variability in steroid production has been described (116) and
an ideal LPS protocol for use after GnRH trigger has not yet
been defined. Patients can be treated with either intensive ste-
roid support (high doses of oral estradiol plus intra-muscular
progesterone) (117) or with low dose hCG, with the dose indi-
vidualized according to the number of oocytes retrieved (118).
Providing LPS via LH activity after agonist trigger is a possi-
bility, as LH would stimulate corpora lutea to produce proges-
terone and other steroids. This could be done with LH directly,
but this is inconvenient as it requires LH injections every
48 hours and is unlikely to be cost-effective. An alternative
suggested by Humaidan et al. is to use low dose hCG (118),
but this may increase the risk for OHSS after using a GnRH
agonist trigger if hCG dosing is inadequate. Otherwise, all oo-
cytes or embryos can be frozen rather than transferred, to
avoid secondary OHSS if the patient gets pregnant (119). Dur-
ing HRT FET cycles, the luteal phase needs to be fully sup-
ported rather than supplemented, and progesterone is
always needed after priming of the endometrium with
estrogens.973
VIEWS AND REVIEWSTraditionally, patients start progesterone supplementa-
tion around the time of oocyte pick-up after hCG trigger,
although starting on the day of the oocyte pick-up does
not improve outcomes compared with starting 6 days later
(115). Once LPS is initiated, most physicians do not
monitor progesterone serum levels to titrate the dose of
medication until withdrawal, rather serum levels are main-
tained empirically until weeks 10–12 of pregnancy. Howev-
er, individual differences in absorption of the medication
and patient compliance may have a clinical impact or
affect the timing of treatment, meaning individualization
of LPS is needed.
It is well known that vaginal progesterone and uterine
levels do not correlate well with serum levels (120, 121),
however, testing serum samples is the only way to monitor
individual absorption into peripheral blood. Labarta et al.
(122) recently demonstrated that serum levels of
progesterone vary on the day of ET in women undergoing
oocyte donation supplemented with micronized vaginal
progesterone (400 mg twice per day), with lower pregnancy
rates in patients with serum progesterone <9.2 ng/mL
compared with patients with progesterone R9.2 ng/mL. The
WOI may also vary among women with infertility, but more
research is needed to evaluate if and how serum
progesterone and estradiol levels can be used to guide
personalized LPS (116).
Stimulated ART cycles in which the corpus luteum is pre-
sent do not need additional progesterone support after the
pregnancy test, as the hCG used for triggering supports the
corpus luteum for 5–7 days. Exogenous progesterone will
then support the endometrium until pregnancy, after which
sufficient hCG is secreted to support the pregnancy. Once
hCG is detected in the blood, there is no need to maintain pro-
gesterone supplementation (123–126). In HRT FET cycles, in
which there is no corpus luteum, support is required until
the luteo–placental shift takes place.Obstetric Management
Multiple pregnancies resulting from the transfer of multiple
embryos are a cause of significant adverse obstetric, fetal,
perinatal and neonatal risks, but can be resolved with SET
and FET. Other ART procedures, such as oocyte donation,
have consistently been associated with increased risk of
adverse obstetric and perinatal outcomes (127, 128). There
is accumulating evidence of a higher risk of large-for-
gestational-age infants and higher birth weight with FET
compared with fresh ET, and fresh transfers are associated
with higher risks of preterm birth, low birth weight and
born small-for-gestational-age (129). When attributing risks
to ART, it is important to note that the above-mentioned as-
sociations are based on observational studies, and that the
pregnancy complications may be related to infertility itself
and not to the treatment. Moreover, it is currently unknown
whether higher surveillance is warranted with ART pregnan-
cies. Themost important group of infertile women that require
special attention in pregnancy are women with PCOS who
become pregnant, specifically those with the hyperandro-
genic phenotype (130, 131).974HOW CAN THE SUPERIORITY OF
PERSONALIZED ART TREATMENT COMPARED
WITH STANDARDIZED ART TREATMENT BE
ESTABLISHED?
A number of factors may influence the outcome of treatment,
including the characteristics of the couple and the treatment
strategy selected, and these are also likely to interact. It
may be possible to identify specific patient characteristics
(e.g. female age, BMI, and duration or cause of infertility,
AFC, AMH or previous ovarian response) that enable optimal
treatment selection (stratified treatment). It must be empha-
sized, however, that when evaluating personalized medicine
the prognosis should not be considered alone, and the
benefit–harm balance of the treatment relative to the individ-
ual patient profile should be a major consideration for treat-
ment selection. As such, personalized treatment requires
sound evidence from strong scientific research to identify
these subgroups, and to show that they genuinely differ in
outcomes or benefit–harm balance.
The rationale for a personalized approach is likely to
come from retrospective analyses of large observational
studies or real-world data. Such analyses may suggest inter-
action between baseline features, markers or test results on
one hand and treatment outcomes on the other. Analytical
methods such as propensity scoring can be used to reduce
biases to a lack of comparability in baseline and treatment
characteristics between groups. Given the often small differ-
ences that are expected between personalized and standard
approaches, such methods will rarely provide definitive
evidence.
Thus, the value of personalized treatment selection
markers should be evaluated in properly designed clinical tri-
als. While it might seem obvious to directly compare a person-
alized strategy and the standard, one-size-fits-all strategy in
eligible patients, one should realize that differences in
outcome will only occur in those patients in whom the
personalized treatment strategy differs from the one-size-
fits-all strategy. As one may consider changing treatment
for a subgroup only, a more efficient, targeted comparative
trial would randomize only patients or couples for whom
the personalized approach would differ from the previous,
standard approach (132).
In certain cases, single-arm observational studies can
generate the knowledge necessary for a personalized
approach. This may apply if such studies can convincingly
demonstrate the absence of a desired outcome after specific
treatments in one subgroup, but not in others, demonstrating
the absence of a treatment benefit in the former.
Despite the interest in personalized medicine, many trials
do not report outcomes according to patient characteristics;
rather, the focus is on reporting only the main outcomes
without secondary analyses. We recommend that every RCT
should include secondary analyses exploring potential treat-
ment selection markers that identify differences in benefits
across subgroups. These secondary analyses should ideally
be performed with properly a priori specified hypotheses, if
well-supported by prior evidence, or by original and relevant
scientific rationale if prior evidence is not available. WhereVOL. 109 NO. 6 / JUNE 2018
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cient power and precision, enabling separate publication.
However, it will not always be possible to provide sufficient
power for secondary analyses, and in such situations explor-
atory secondary analyses (ideally pre-specified in study pro-
tocol, but also valuable as post hoc analyses to explain
unexpected results) can still be useful to inspire further inves-
tigation and eventual confirmation in other trials, and the re-
sults could be included in a systematic review.
As ART is a stepwise process and involves a number of
important treatment decisions at different time points, opti-
mization at each time point may be expected to, but not
necessarily, result in a globally optimized treatment protocol.
As a result of this, it would be nearly impossible to compare
the differences between all different treatment options
throughout the ART treatment journey using a standard study
design, owing to the unrealistic sample size and number of
treatment arms required, in addition to concerns of
heterogeneity.
Heterogeneity not only exists at the level of patients
(age, duration and cause of infertility, ovarian reserve, num-
ber and type of previous infertility therapies, and related re-
sponses, with ovarian response to OS possibly influenced by
genetic polymorphisms for LH, FSH and their receptors)
(133), but can also arise from the knowledge, skill and opin-
ions of different healthcare professionals (doctors, embryol-
ogists and nurses) in different centers. This heterogeneity is
known to affect intermediate outcomes during ART treat-
ment, such as the number of follicles observed by ultrasound
scan during OS, number of oocytes retrieved after oocyte
aspiration, pregnancy rate per ET, oocyte damage rate and
fertilization rate after ICSI, and survival rate of cryopre-
served embryos after warming/thawing. This heterogeneity
in treatment effect, contributed to by both patients and
healthcare professionals, results in the known center effect
(134, 135), which explains why it has been impossible so
far to apply models predicting pregnancy or live birth in
the real world (134).
As the benefits from personalized ART treatment may be
small yet clinically relevant, future multicenter trials could try
to minimize the variability from center effects. Proof-of-
principle evidence of the benefits of using a personalized
approach can also be obtained in separate trials using the
same study protocol in selected centers, with invitations
based upon their established interest, commitment, trial
expertise, and experience in addressing the primary study
question. The selection of centers needs to be as fair as
possible and efforts would be needed to ensure the selection
is not influenced by economic, political and academic bias.
The studies should aim to demonstrate proportional improve-
ments in intermediate outcomes (i.e. number and quality of
oocytes/embryos) and ultimately in CPRs and LBRs, as well
as safety, effectiveness in terms of patient-centered outcomes,
and cost-effectiveness. In addition, when personalized ART
treatment is compared with standard ART treatment, these
studies should be conducted in well characterized patient
phenotypes. In any case, the outcomes observed in trials in
selected centers should subsequently be confirmed using reg-
istries reflecting care in the real world.VOL. 109 NO. 6 / JUNE 2018Overall, this highlights that both innovative study designs
and outcome assessment methods need to be further devel-
oped before a globally optimized, personalized treatment pro-
tocol can be easily produced.CONCLUSION
One can wonder whether any form of standardized care can
exist without taking the personal characteristics, concerns
and aspirations of a couple into account, and whether person-
alized care can exist without any form of standardization.
Any form of quality care will be, to some extent, both stan-
dardized and personalized.
In this review, we have identified the most relevant and
emerging areas of personalized ART and have proposed
several approaches, taking the specific characteristics and as-
pirations of the couple into account, to develop more solid ev-
idence of the (differential) effectiveness, safety, cost and
treatment burden for the couples involved.
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